Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH J HAUKE

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1578511283
CMS profile
297671
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$16.02

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $16.02 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Pharmacyclics LLC, An AbbVie Company $16.02 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH J HAUKE

NPI 1578511283 · CMS profile ID 297671

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
RALPH J HAUKE, NPI 1578511283, CMS profile ID 297671, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1578511283?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $16.02 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Pharmacyclics LLC, An AbbVie Company $16.0208/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 998286895 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $7,629.00 9
PY2020 $7.49 1
PY2021 $780.92 3
PY2023 $16.02 1
PY2024 $225.23 10
PY2025 $31.33 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $609.30 2
PY2025 Principal investigator $1,167,738.55 292
PY2024 Principal investigator $1,299,594.58 212
PY2023 Principal investigator $2,735,258.21 252
PY2022 Recipient $4,157.00 1
PY2022 Principal investigator $1,567,591.67 137
PY2021 Principal investigator $2,060,900.77 213
PY2020 Recipient $705.81 1
PY2020 Principal investigator $1,867,000.72 289
PY2019 Principal investigator $1,377,455.65 354

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

213 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $7,840.42 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma No dispute reported 06/30/2026 848742719
Principal investigator 1 Merck Sharp & Dohme Corporation $1,216.54 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab with or without Platinum-Based Combination Chemotherapy versus Chemotherapy in Subjects with Advanced or Metastatic Urothelial Carcinoma No dispute reported 06/30/2026 848745035
Principal investigator 1 Merck Sharp & Dohme Corporation $4,359.24 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 848747047
Principal investigator 1 Merck Sharp & Dohme Corporation $24,773.73 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 848747197
Principal investigator 1 Merck Sharp & Dohme Corporation $736,133.98 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide versus Placebo Plus Enzalutamide in Participants with Metastatic Castration-Resistant Prostate Cancer mCRPC KEYNOTE-641 No dispute reported 06/30/2026 848747233
Principal investigator 1 Merck Sharp & Dohme Corporation $19,548.39 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 848749363
Principal investigator 1 Merck Sharp & Dohme Corporation $29,270.11 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 3, Randomized, Double-blind Study of Pembrolizumab MK-3475 Plus Docetaxel Plus Prednisone versus Placebo Plus Docetaxel Plus Prednisone in Participants with Chemotherapy-na Metastatic Castration-Resistant Prostate Cancer mCRPC who have Progressed on a Next Generation Hormonal Agent NHA KEYNOTE-921 No dispute reported 06/30/2026 848750087
Principal investigator 1 Merck Sharp & Dohme Corporation $37,051.70 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 848750129
Principal investigator 1 Merck Sharp & Dohme Corporation $15,805.35 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 848750131
Principal investigator 1 Merck Sharp & Dohme Corporation $39,181.21 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 848750227
Principal investigator 1 Merck Sharp & Dohme Corporation $14,822.66 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer KEYNOTE-B99 No dispute reported 06/30/2026 848750265
Principal investigator 1 Merck Sharp & Dohme Corporation $8,687.05 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 848752463
Principal investigator 1 Merck Sharp & Dohme Corporation $781.74 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 848752465
Principal investigator 1 Merck Sharp & Dohme Corporation $1,115.69 12/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Multi-center, Double-Blind, Randomized Phase 3 Study to Compare the Efficacy and Safety of Belzutifan MK-6482 plus Pembrolizumab MK- 3475 Versus Placebo plus Pembrolizumab, in the Adjuvant Treatment of Clear Cell Renal Cell Carcinoma ccRCC Post Nephrectomy 6482-022 No dispute reported 06/30/2026 848753823
Principal investigator 1 Merck Sharp & Dohme Corporation $1,640.80 12/20/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase I,II Study of MK-3475 SCH900475 in Combination with Chemotherapy and,or Immunotherapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma No dispute reported 06/30/2026 848742677
Principal investigator 1 Janssen Research & Development, LLC $824.00 12/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727247
Principal investigator 1 Janssen Research & Development, LLC $825.00 12/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727265
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $750.00 12/01/2021 Non-covered Recipient Entity
Hematology / Oncology West Pc
Phase III Adjuvant Melanoma Stage II B C Opdivo Mono No dispute reported 06/30/2026 819894965
Principal investigator 1 BioNTech SE $9,419.00 11/24/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137625
Principal investigator 1 Exelixis Inc. $1,408.87 11/19/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838856995
Principal investigator 1 Exelixis Inc. $1,950.00 11/19/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857095
Principal investigator 1 Exelixis Inc. $195.00 11/19/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838857097
Principal investigator 1 Orion Corporation $16,750.00 11/18/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P C
CYPIDES No dispute reported 06/30/2026 765687460
Principal investigator 1 Exelixis Inc. $750.00 11/17/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838856945
Principal investigator 1 Janssen Research & Development, LLC $825.00 11/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727213
Principal investigator 1 Janssen Research & Development, LLC $933.00 11/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727231
Principal investigator 1 BioNTech SE $4,565.35 11/11/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137783
Principal investigator 1 Merck Sharp & Dohme Corporation $16,750.00 10/27/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase 1b,2 Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination with Investigational Agents for the Treatment of Participants With PD-1,L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy KEYNOTE-B98 No dispute reported 06/30/2026 848750127
Principal investigator 1 Eisai Inc. $956.00 10/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169953
Principal investigator 1 Incyte Corporation $1,063.00 10/15/2021 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 831102053
Principal investigator 1 Janssen Research & Development, LLC $933.00 10/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727145
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 10/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727161
Principal investigator 1 Janssen Research & Development, LLC $825.00 10/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727179
Principal investigator 1 Janssen Research & Development, LLC $933.00 10/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727195
Principal investigator 1 BioNTech SE $13,703.00 10/13/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137539
Principal investigator 1 PFIZER INC. $7,500.00 10/08/2021 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 832605527
Principal investigator 1 Astellas Pharma Global Development $13,288.00 10/06/2021 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801078959
Principal investigator 1 Astellas Pharma Global Development $3,322.00 10/06/2021 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801078961
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $500.00 10/06/2021 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors No dispute reported 06/30/2026 786498475
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,500.00 10/04/2021 Non-covered Recipient Entity
Us Oncology Research Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 789148113
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $600.00 10/04/2021 Non-covered Recipient Entity
Us Oncology Research Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 789149379
Principal investigator 1 Merck Sharp & Dohme Corporation $44,264.40 09/29/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab MK-3475 as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy No dispute reported 06/30/2026 848747009
Principal investigator 1 Exelixis Inc. $3,900.00 09/24/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854593
Principal investigator 1 Exelixis Inc. $65.00 09/24/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854595
Principal investigator 1 Exelixis Inc. $260.00 09/24/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854597
Principal investigator 1 BioNTech SE $5,288.70 09/22/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137473
Principal investigator 1 Exelixis Inc. $2,271.20 09/17/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854407
Principal investigator 1 Janssen Research & Development, LLC $933.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726903
Principal investigator 1 Janssen Research & Development, LLC $933.00 09/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726919
Principal investigator 1 Exelixis Inc. $1,135.60 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854169
Principal investigator 1 Exelixis Inc. $1,172.40 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854207
Principal investigator 1 Exelixis Inc. $1,495.00 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854299
Principal investigator 1 Exelixis Inc. $3,900.00 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854301
Principal investigator 1 Exelixis Inc. $65.00 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854303
Principal investigator 1 Exelixis Inc. $260.00 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838854305
Principal investigator 1 Exelixis Inc. $4,016.67 09/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854339
Principal investigator 1 BioNTech SE $540.33 08/31/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137483
Principal investigator 1 Exelixis Inc. $1,950.00 08/31/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854089
Principal investigator 1 Exelixis Inc. $65.00 08/31/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854091
Principal investigator 1 Exelixis Inc. $195.00 08/31/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838854093
Principal investigator 1 Janssen Research & Development, LLC $933.00 08/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726855
Principal investigator 1 Janssen Research & Development, LLC $933.00 08/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726873
Principal investigator 1 Janssen Research & Development, LLC $933.00 08/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726887
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 08/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727031
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 08/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727049
Principal investigator 1 Merck Sharp & Dohme Corporation $64,289.80 08/13/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC DBA NEBRASKA CANCER SPECIALISTS
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma No dispute reported 06/30/2026 848752461
Principal investigator 1 Astellas Pharma Global Development $34,376.60 07/29/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801080603
Principal investigator 1 Eisai Inc. $956.00 07/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169925
Principal investigator 1 Incyte Corporation $1,063.00 07/15/2021 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 831101983
Principal investigator 1 Janssen Research & Development, LLC $933.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726841
Principal investigator 1 Janssen Research & Development, LLC $933.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726937
Principal investigator 1 Janssen Research & Development, LLC $933.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726951
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726969
Principal investigator 1 Janssen Research & Development, LLC $1,907.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726983
Principal investigator 1 Janssen Research & Development, LLC $1,697.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787726999
Principal investigator 1 Janssen Research & Development, LLC $1,103.00 07/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727015
Principal investigator 1 Exelixis Inc. $1,356.60 07/14/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838853849
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 07/13/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 803526673
Principal investigator 1 Merck Sharp & Dohme Corporation $13,964.00 07/09/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I,II clinical trial to study the safety and tolerability of MK-3475 Pegylated Interferon alfa-2b PEG-IFN and MK-3475 Ipilimumab IPI in Subjects with Advanced Melanoma MEL and Renal Cell Carcinoma RCC No dispute reported 06/30/2026 848742465
Principal investigator 1 PFIZER INC. $7,500.00 07/09/2021 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 832607383
Principal investigator 1 BioNTech SE $2,500.00 07/08/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137475
Principal investigator 1 BioNTech SE $3,000.00 07/08/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137477
Principal investigator 1 BioNTech SE $3,250.00 07/08/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137479
Principal investigator 1 BioNTech SE $11,500.00 07/08/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
BNT111-01 No dispute reported 06/30/2026 851137481
Principal investigator 1 Exelixis Inc. $4,105.07 07/07/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853785
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,000.00 07/02/2021 Non-covered Recipient Entity
Us Oncology Res Llc
A Dose Frequency Optimization, Phase IIIB/IV Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects with Advanced or Metastatic Non-small Cell Lung Cancer who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks. No dispute reported 06/30/2026 819906021
Principal investigator 1 Exelixis Inc. $3,732.69 06/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838853205
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,000.00 06/17/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A Phase 2 Randomized Double-blind Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) No dispute reported 06/30/2026 819898731
Principal investigator 1 Janssen Research & Development, LLC $933.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727297
Principal investigator 1 Janssen Research & Development, LLC $665.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727313
Principal investigator 1 Janssen Research & Development, LLC $933.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727331
Principal investigator 1 Janssen Research & Development, LLC $933.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727347
Principal investigator 1 Janssen Research & Development, LLC $933.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727367
Principal investigator 1 Janssen Research & Development, LLC $933.00 06/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727498
Principal investigator 1 Novartis Pharmaceuticals Corporation $900.00 06/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST NEBRASKA CANCER SPECIALIST
AN OPEN LABEL MULTI CENTER EVEROLIMUS ROLLOVER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED EVEROLIMUS STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED EVEROLIMUS TREATMENT No dispute reported 06/30/2026 800639477
Principal investigator 1 Exelixis Inc. $1,135.60 06/14/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838853085
Principal investigator 1 Exelixis Inc. $1,495.00 06/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852957
Principal investigator 1 Exelixis Inc. $7,800.00 06/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852959
Principal investigator 1 Exelixis Inc. $326.00 06/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852961
Principal investigator 1 Exelixis Inc. $130.00 06/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852963
Principal investigator 1 Exelixis Inc. $520.00 06/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852965
Principal investigator 1 Merck Sharp & Dohme Corporation $52,000.00 06/03/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST P.C. DBA NEBRASKA CANCER SPECIALISTS
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 in Subjects with Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 848767083
Principal investigator 1 Genentech, Inc. $10.00 05/24/2021 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
PHASE III OPEN LABEL RANDOMIZED IN PATS W NSCLC No dispute reported 06/30/2026 835988417
Principal investigator 1 MACROGENICS, INC. $280.00 05/18/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838711725
Principal investigator 1 Astellas Pharma Global Development $6,644.00 05/17/2021 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Multinational Phase 3 Randomized Double-blind Placebo-controlled Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 801078957
Principal investigator 1 Eisai Inc. $899.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169929
Principal investigator 1 Eisai Inc. $520.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169933
Principal investigator 1 Eisai Inc. $520.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169937
Principal investigator 1 Eisai Inc. $565.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169941
Principal investigator 1 Eisai Inc. $450.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169945
Principal investigator 1 Eisai Inc. $565.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169949
Principal investigator 1 Eisai Inc. $899.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170025
Principal investigator 1 Eisai Inc. $450.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170029
Principal investigator 1 Eisai Inc. $520.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170034
Principal investigator 1 Eisai Inc. $565.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170037
Principal investigator 1 Eisai Inc. $565.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170041
Principal investigator 1 Eisai Inc. $23.00 05/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170053
Principal investigator 1 Janssen Research & Development, LLC $1,490.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727413
Principal investigator 1 Janssen Research & Development, LLC $933.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727431
Principal investigator 1 Janssen Research & Development, LLC $1,490.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727449
Principal investigator 1 Janssen Research & Development, LLC $933.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727465
Principal investigator 1 Janssen Research & Development, LLC $933.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727483
Principal investigator 1 Janssen Research & Development, LLC $218.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787727515
Principal investigator 1 Janssen Research & Development, LLC $547.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787727533
Principal investigator 1 Janssen Research & Development, LLC $145.00 05/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787727549
Principal investigator 1 Novartis Pharmaceuticals Corporation $197,631.82 05/15/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
AN OPEN-LABEL, RANDOMIZED, PHASE III STUDY COMPARING 177LU-PSMA-617 IN COMBINATION WITH STANDARD OF CARE, VERSUS STANDARD OF CARE ALONE, IN ADULT MALE PATIENTS WITH METASTATIC HORMONE SENSITIVE PROSTATE CANCER (MHSPC) No dispute reported 06/30/2026 800637141
Principal investigator 1 Exelixis Inc. $1,272.96 05/12/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852565
Principal investigator 1 Exelixis Inc. $1,345.55 05/12/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852617
Principal investigator 1 Pharmacyclics LLC, an AbbVie Company $500.00 05/12/2021 Covered Recipient Teaching Hospital
NEBRASKA METHODIST HOSPITAL
A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors No dispute reported 06/30/2026 786498473
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,050.00 04/28/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study No dispute reported 06/30/2026 819898719
Principal investigator 1 Exelixis Inc. $1,560.00 04/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852503
Principal investigator 1 Exelixis Inc. $1,950.00 04/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852505
Principal investigator 1 Exelixis Inc. $65.00 04/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852507
Principal investigator 1 Exelixis Inc. $195.00 04/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852509
Principal investigator 1 Astellas Pharma Global Development $4,516.99 04/22/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801080029
Principal investigator 1 Astellas Pharma Global Development $25,124.25 04/22/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801080031
Principal investigator 1 PFIZER INC. $7,500.00 04/22/2021 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 832607373
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 04/20/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 803526671
Principal investigator 1 Eisai Inc. $450.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170017
Principal investigator 1 Eisai Inc. $2,134.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170021
Principal investigator 1 Eisai Inc. $956.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170045
Principal investigator 1 Eisai Inc. $899.00 04/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170049
Principal investigator 1 Incyte Corporation $1,063.00 04/15/2021 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 831101917
Principal investigator 1 Janssen Research & Development, LLC $933.00 04/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727281
Principal investigator 1 Janssen Research & Development, LLC $933.00 04/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727383
Principal investigator 1 Janssen Research & Development, LLC $933.00 04/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer No dispute reported 06/30/2026 787727396
Principal investigator 1 Novartis Pharmaceuticals Corporation $71,031.11 04/15/2021 Non-covered Recipient Entity
GU RESEARCH NETWORK LLC
PSMAFORE: A PHASE III, OPEN-LABEL, MULTI-CENTER, RANDOMIZED STUDY COMPARING 177LU-PSMA-617 VS. A CHANGE OF ANDROGEN RECEPTOR-DIRECTED THERAPY IN THE TREATMENT OF TAXANE NAIVE MEN WITH PROGRESSIVE METASTATIC CASTRATE RESISTANT PROSTATE CANCER No dispute reported 06/30/2026 800631995
Principal investigator 1 Exelixis Inc. $4,165.85 04/14/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852143
Principal investigator 1 Exelixis Inc. $2,003.45 04/14/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838852297
Principal investigator 1 Exelixis Inc. $3,983.52 04/14/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838852457
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $567.86 03/25/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialist
PhII 1L NSCLC Dose Safety, CoC Biomarker Evaluation No dispute reported 06/30/2026 819898683
Principal investigator 1 PFIZER INC. $7,500.00 03/24/2021 Non-covered Recipient Entity
US Oncology Research LLC
TREATMENT RESISTANCE FOLLOWING ANTICANCER THERAPIESTRANSLATE No dispute reported 06/30/2026 832605517
Principal investigator 1 Exelixis Inc. $3,000.50 03/17/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850227
Principal investigator 1 Exelixis Inc. $1,135.60 03/17/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850707
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $25,704.80 03/16/2021 Non-covered Recipient Entity
Us Oncology Research Llc
Bay88-8223 Alpharadin Combo with abiraterone in CRPC No dispute reported 06/30/2026 789136763
Principal investigator 1 Exelixis Inc. $1,560.00 03/10/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850407
Principal investigator 1 Exelixis Inc. $3,900.00 03/10/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850409
Principal investigator 1 Exelixis Inc. $130.00 03/10/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850411
Principal investigator 1 Exelixis Inc. $390.00 03/10/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850413
Principal investigator 1 MACROGENICS, INC. $15,262.78 03/10/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838710755
Principal investigator 1 MACROGENICS, INC. $6,494.80 03/10/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838710761
Principal investigator 1 MACROGENICS, INC. $10,716.42 03/10/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
SAFETY STUDY OF ENOBLITUZUMAB MGA271 IN COMBINATION WITH PEMBROLIZUMAB OR MGA012 IN REFRACTORY CANCER No dispute reported 06/30/2026 838710767
Principal investigator 1 Gilead Sciences, Inc. $1,250.00 03/09/2021 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/PD-L1 Based Immunotherapy No dispute reported 06/30/2026 803526669
Principal investigator 1 Astellas Pharma Global Development $11,080.30 03/04/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801079611
Principal investigator 1 Exelixis Inc. $780.00 03/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850585
Principal investigator 1 Exelixis Inc. $6,639.94 03/03/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850613
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $217.90 02/23/2021 Non-covered Recipient Entity
Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 819897485
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $6,104.00 02/12/2021 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 819906112
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $17,081.50 02/09/2021 Non-covered Recipient Entity
Us Oncology Res Llc
A Phase IIIb/IV Safety Trial of Nivolumab (BMS-936558) in Subjects with Advanced or Metastatic Renal Cell Carcinoma Who Have Progressed During or After Receiving One Prior Systemic Regimen No dispute reported 06/30/2026 819905161
Principal investigator 1 Astellas Pharma Global Development $9,112.57 02/08/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801079483
Principal investigator 1 Exelixis Inc. $3,900.00 02/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850061
Principal investigator 1 Exelixis Inc. $326.00 02/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850063
Principal investigator 1 Exelixis Inc. $65.00 02/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850065
Principal investigator 1 Exelixis Inc. $437.00 02/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850067
Principal investigator 1 Exelixis Inc. $260.00 02/04/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838850069
Principal investigator 1 Astellas Pharma Global Development $5,408.49 02/01/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801079435
Principal investigator 1 Exelixis Inc. $1,408.87 01/28/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 838850025
Principal investigator 1 Exelixis Inc. $5,043.05 01/21/2021 Non-covered Recipient Entity
Oncology Hematology West, P.C.
A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris No dispute reported 06/30/2026 838849559
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $48,124.00 01/20/2021 Non-covered Recipient Entity
Us Oncology Res Llc
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 819906437
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,824.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Nivo RCC Safety Trial No dispute reported 06/30/2026 819898689
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,404.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 819898695
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,740.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Phase IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 819898707
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $3,400.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Nivo Dose Frequency Optimization Lung Trial No dispute reported 06/30/2026 819898713
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $32,128.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematology West P.c. Dba Nebraska Cancer Specialists
Ph III MIBC Neoadjuvant 1L Bladder IDO Nivo chemo No dispute reported 06/30/2026 819898725
Principal investigator 1 Eisai Inc. $450.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169957
Principal investigator 1 Eisai Inc. $520.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169961
Principal investigator 1 Eisai Inc. $520.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169965
Principal investigator 1 Eisai Inc. $565.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169969
Principal investigator 1 Eisai Inc. $899.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169973
Principal investigator 1 Eisai Inc. $450.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169977
Principal investigator 1 Eisai Inc. $899.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169981
Principal investigator 1 Eisai Inc. $565.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169985
Principal investigator 1 Eisai Inc. $899.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169989
Principal investigator 1 Eisai Inc. $565.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169993
Principal investigator 1 Eisai Inc. $565.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836169999
Principal investigator 1 Eisai Inc. $450.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170001
Principal investigator 1 Eisai Inc. $899.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170005
Principal investigator 1 Eisai Inc. $450.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170009
Principal investigator 1 Eisai Inc. $956.00 01/15/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST, PC LAKESIDE
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR) No dispute reported 06/30/2026 836170013
Principal investigator 1 Incyte Corporation $1,063.00 01/15/2021 Covered Recipient Teaching Hospital
Nebraska Methodist Hospital
A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations No dispute reported 06/30/2026 831101887
Principal investigator 1 Janssen Research & Development, LLC $393.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726727
Principal investigator 1 Janssen Research & Development, LLC $145.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726745
Principal investigator 1 Janssen Research & Development, LLC $145.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726762
Principal investigator 1 Janssen Research & Development, LLC $145.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726777
Principal investigator 1 Janssen Research & Development, LLC $145.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726793
Principal investigator 1 Janssen Research & Development, LLC $218.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726811
Principal investigator 1 Janssen Research & Development, LLC $145.00 01/15/2021 Non-covered Recipient Entity
Oncology Hematlgy W PC
Biomarker Study to Determine Frequency of DNA repair Defects in Men with Metastatic Prostate Cancer No dispute reported 06/30/2026 787726823
Principal investigator 1 Novartis Pharmaceuticals Corporation $146.52 01/15/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY COMPARING THE COMBINATION OF PDR001 DABRAFENIB AND TRAMETINIB VERSUS PLACEBO DABRAFENIB AND TRAMETINIB IN PREVIOUSLY UNTREATED PATIENTS WITH UNRESECTABLE OR METASTATIC BRAF V600 MUTANT MELANOMA No dispute reported 06/30/2026 800637153
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,621.52 01/15/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
TWO ARM RANDOMIZED PHASE 3 STUDY IN HIGH RISK NSCLC COMPARING CANAKINUMAB VS PLACEBO IN ADJUVANT SETTING No dispute reported 06/30/2026 800637159
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,493.00 01/13/2021 Non-covered Recipient Entity
Us Oncology Res Llc
Phase IIB Prostate Combos PARP Enza Chemo No dispute reported 06/30/2026 819904891
Principal investigator 1 AstraZeneca AB $42,674.37 01/11/2021 Non-covered Recipient Entity
NEBRASKA CANCER SPECIALISTS
A Phase I, Open-label, Multi-centre Study to Assess the Safety, Tolerability, and Pharmacokinetics of Capivasertib (AZD5363) in Combination with Novel Agents in Patients with Advanced Prostate Cancer No dispute reported 06/30/2026 826490815
Principal investigator 1 Astellas Pharma Global Development $7,921.75 01/07/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801079325
Principal investigator 1 Astellas Pharma Global Development $11,080.24 01/07/2021 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY WEST PC
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) No dispute reported 06/30/2026 801079327